RA
LGND icon

Rise Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Rise Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-84
Closed -$14.9K – 842
2025
Q3 		$14.9K Hold
84
– – 0.01% 760
2025
Q2 		$9.55K Hold
84
– – ﹤0.01% 1020
2025
Q1 		$8.83K Buy
+84
New +$9.5K ﹤0.01% 1065

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Rise Advisors's LGND Position: Q4 2025 in Review

Rise Advisors sold out of Ligand Pharmaceuticals (LGND) in Q4 2025, closing a stake of 84 shares — an estimated $14.9K sold.

Rise Advisors first reported a position in LGND in Q1 2025 and held it in 3 quarters. The position peaked at $14.9K in Q3 2025. 349 funds tracked by Wall St. Rank hold LGND as of Q4 2025.

  • Rise Advisors reported no remaining Ligand Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Rise Advisors sold 84 Ligand Pharmaceuticals shares in Q4 2025, an estimated $14.9K.
  • Rise Advisors first reported a position in Ligand Pharmaceuticals in Q1 2025 and held it in 3 quarters.
  • Rise Advisors's Ligand Pharmaceuticals position peaked at $14.9K in Q3 2025.
  • 349 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.